Clinical Trial Update: A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

This is a Phase 1 trial evaluating ipatasertib plus palbociclib and fulvestrant versus placebo plus palbociclib and fulvestrant in hormone receptor-positive, HE…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Palbociclib (palbociclib)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Phase 1 | Status: TERMINATED | Results posted: 2024-11-08